CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 87 enrolled
Drug / intervention
IDN-6556 +1 moredrug
Likely dose
IDN-6556 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02230670
NCT02230670Phase 2Completed
CompareCT.gov

A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis

Conatus Pharmaceuticals Inc.·interventional·Posted Sep 3, 2014·Updated Jul 5, 2017

In Brief

A Phase 2 clinical trial evaluating IDN-6556 and Placebo for Liver Cirrhosis and Hepatic Cirrhosis. Completed, enrolled 87 participants across 28 sites.

Detailed Summary

This is a multicenter study to see if treatment with IDN-6556 can help improve the liver function of patients with liver cirrhosis with Model for End-Stage Liver Disease scores between 11-18.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis, Hepatic Cirrhosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 3, 2014
Enrollment StartAug 1, 2014
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.8 years ago

Interventions

IDN-6556drug

25 mg BID

Placebodrug